|
Pertussis
Outbreak in Utah, 1998
Background
During the first week of August
1998, the Communicable Disease Control Program was contacted by one of Utahs 12
local health districts to report three cases of pertussis among staff at a local hospital.
Thirty-four cases of pertussis had been reported to the Bureau of Epidemiology to date for
1998 and six of those cases were among adults (this includes three 1997 cases reported in
1998). At that time the Utah Immunization Program assisted with a newsletter article
"Pertussis Persists in Children and Adults," (Epidemiology Newsletter, July
1998) to provide an update on pertussis in Utah and to encourage health care providers to
consider pertussis in both children and adults who present with a cough illness.
Four weeks later, 50 cases of pertussis had been reported in Utah for
1998 and hundreds of suspect cases had been identified in seven local health districts.
The Utah Department of Health issued a state-wide pertussis alert and implemented active
surveillance for pertussis. Many of the cases were occurring in populations that have
traditionally had low immunization rates. By the end of November, 242 cases have been
reported and many suspect cases are still under investigation.
Investigation
Since the first of July 1998, 26
children have been hospitalized with symptoms consistent with pertussis. Seven of the
children hospitalized were from a rural area of the state. Their ages ranged from three
months to three years with four of these patients under the age of six months. The other
19 children were hospitalized in Salt Lake County and their ages ranged from two weeks to
two years. No adults have been hospitalized and no fatalities have been reported.
Ninety-one confirmed and 154 probable cases have been identified
in addition to 217 suspect cases. Confirmed and probable cases
are defined using the Centers for Disease Control and Prevention
(CDC), MMWR Recommendations and Reports, May 2, 1997, "Case
Definitions for Infectious Conditions Under Public Health Surveillance".
Confirmed is defined as a case that is: 1) laboratory
confirmed by isolation of Bordetella pertussis from a
clinical specimen or a positive polymerase chain reaction for
B. pertussis, or 2) one that meets the clinical case
definition and is either laboratory confirmed or epidemiologically
linked to a laboratory-confirmed case. The clinical case definition
is a cough illness lasting > 2 weeks with one of the
following: paroxysms of coughing, inspiratory "whoop",
or post-tussive vomiting, without other apparent cause. A probable
case is one that meets the clinical case definition, is not
laboratory confirmed, and is not epidemiologically linked to
a laboratory-confirmed case. For purposes of this outbreak,
the Utah Department of Health is defining a suspect case
as any cough illness of unknown etiology. Only confirmed and
probable cases are included in the total case count. The ages
of the cases have ranged from newborn to 72 years (Figure
1) with 61 of those less than one year of age. The dates
of onset of illness have been grouped by month (Figure 2).
The three cases that had onset dates in late 1997 and were not
reported until 1998 are not included.
Figure 1

Figure 2

Staff from the Utah Department of Health traveled to the affected rural
area to assist with the outbreak investigation. It appeared that the outbreak of pertussis
had been ongoing since mid-July and was distributed through most of the community. An
approach of targeted early case identification, prophylaxis of contacts, an accelerated
immunization schedule for infants living in the affected area, and an aggressive education
campaign was chosen as the most practical strategy of management. A separate pertussis
monitoring surveillance system was initiated in order to: 1) rapidly assemble information
on the current outbreak, 2) provide data sufficient to develop an epidemic curve, 3)
determine the number of households with infectious members, 4) characterize compliance
with recommendations for prophylaxis, and 5) determine the frequency of travel outside the
community.
Along the Wasatch Front, which includes Salt Lake County, staff from
the local health districts have identified cases and their contacts to provide prophylaxis
and education. Many of the cases have been among large extended families who frequently
associate with each other. This has assisted in locating contacts of cases to provide
prophylaxis.
The Utah Public Health Laboratory initiated active surveillance in
local health districts with at least one case of pertussis in an effort to look for
adolescents and adults that may be carrying B. pertussis. In addition, the
laboratory has Pulse Field Gel Electrophoresis (PFGE) capability that uses genetic
fingerprinting to track the outbreak and compare these molecular patterns with what is
being seen elsewhere in the U.S. Three patterns have been identified using PFGE. One of
the patterns that is predominant in the rural area was also identified in one of the Salt
Lake County cases that gave a history of travel to the rural site. Epidemiological
linkages are still being investigated but we now know that more than one strain of
pertussis is circulating in the state. From all the reporting laboratories including the
State Public Health Laboratory, 48 cases have been confirmed by culture and 14 of those
were in persons 13 years of age and older.
Recommendations
Transmission of pertussis may be reduced in
household or close contacts by early treatment with an effective antimicrobial agent (Table
1). All household and other close contacts of a pertussis case should receive
treatment, regardless of age and vaccination status. Patients in the early stages of
infection and those with cough illness of less than three weeks duration should also be
treated as soon as possible. For greatest efficacy, antibiotic therapy must be given early
in the course of disease, preferably before the paroxysmal stage of the cough develops.
Young children with symptoms suggestive of pertussis should be evaluated by a health care
provider, provided with antibiotics and information on how to determine if a child should
be reassessed and hospitalized for supportive care. Infants less than one year of age who
demonstrate cough paroxysms with apnea and/or cyanosis should be hospitalized for
supportive care and antibiotic therapy.
Table 1.
| RECOMMENDED
ANTIBIOTIC REGIMENS* |
| First Line Therapy
|
| Erythromycin
(E-mycin, Erye, Ery-Tab) |
| Children |
50 mg/kg per day
divided qid x 14 days (maximum 2 gm/day) |
| Adults |
50 mg/kg per day
divided qid x 14 days (maximum 2 gm/day) |
| Alternative
Regimens |
| Trimethoprim-Sulfamethoxazole
(TMP/SMX, Bactrim, Septra); Dosing based on TMP |
| Children |
TMP 8 mg/kg per day
divided bid x 14 days (Sanford 1996) |
| Adults |
1 DS tab bid x 14
days |
| Pediazole (EES 200
mg/5cc + Sulfisoxazole 600 mg) |
| Children |
50 mg/kg per day
divided qid x 14 days (based on EES, with maximum 2gm/day) |
| Adults |
Not commonly used |
|
Clarithromycin**
|
| Children |
15 mg/kg per day
divided bid x 10 days |
| Adults |
500 mg bid x 10 days |
| Azithromycin** |
| Children |
Not commonly used |
| Adults |
500 mg day #1, 250 mg on days
#2-10 |
Note:
* Antibiotic dosing and duration is the same whether prescribed for prophylaxis or
treatment
* * Azithromycin and Clarithromycin have been considered reasonable alternatives by many
clinicians, though their use has not formally been recommended by the CDC. |
Immunizing children appropriately and on schedule is the
best defense currently available to prevent pertussis. The new pertussis vaccine
(acellular or DTaP) is effective and produces fewer side effects than whole cell DTP
vaccines. A variety of DTaP vaccines are licensed for use in infants and children and have
shown high levels of efficacy. As stated earlier, during this outbreak, we are
recommending an accelerated immunization schedule for infants living in the affected
community. This differs from the regular schedule in that it allows for the initiation of
immunizations at six weeks of age (instead of two months), with the interval between
immunizations reduced to four weeks (instead of eight).
In order to continue to monitor the incidence of pertussis, cultures
should be promptly collected on symptomatic individuals. The preferred specimen is a
nasopharyngeal swab collected early in the course of illness. The later the culture is
obtained (usually after 1-2 weeks), the less likely it is to be helpful in making the
diagnosis.
We strongly encourage health care providers to continue to be
suspicious of pertussis in anyone with a persistent cough or other symptoms consistent
with pertussis. Please report cases or suspect cases to your local health department or to
the Bureau of Epidemiology (801-538-6191).
(Note: The pertussis cases in this article exceed the numbers on the
back of this newsletter. This is a result of counting only confirmed cases in the
Monthly Morbidity Summary.)
Rheumatic
Fever
A presentation by Dr. Lloyd Tani, a
pediatric cardiologist at Primary Childrens Medical Center (PCMC) was recently
featured at the American Heart Associations Scientific Sessions in Dallas, Texas.
Dr. Tani provided an overview of research done on the 478 cases of rheumatic fever seen by
physicians at PCMC since 1985. This study was prompted by a recent increase in the
reported cases of rheumatic fever in Utah (for details see: May, 1998 Epidemiology
Newsletter, Rheumatic Fever in Utah, 1998: (When a sore throat isnt just a sore
throat.....). Researchers are trying to gain an understanding of why the incidence is
increasing, so that possible control measures can be identified. In cooperation with this
research, the Bureau of Epidemiology routinely provides data on reported rheumatic fever
cases. For the data to be as accurate as possible, it is important that all suspect and
confirmed rheumatic fever cases are promptly reported to the Bureau of Epidemiology. For
questions about reporting these cases, please contact the Bureau of Epidemiology at (801)
538-6191.
Utah Department of
Health, Bureau of Epidemiology
Monthly
Morbidity Summary - November 1998 - Provisional Data

The Epidemiology Newsletter is published monthly by the
Utah Department of Health, Division of Epidemiology and Laboratory Services, Bureau of
Epidemiology, to disseminate epidemiologic information to the health care professional and
the general public.
Send comments to:
The Bureau of Epidemiology
Box 142104
Salt Lake City, UT 84114-2104
or call (801) 538-6191
Approval 8000008: Appropriation 3705
Rod Betit, Executive Director Utah Department of Health
Charles Brokopp, Dr.P.H. Division of Epidemiology and Laboratory Services
Craig R Nichols, MPA, Editor, State Epidemiologist, Director Bureau of Epidemiology
Cristie Chesler, BA Managing Editor |